ISTH: Apixaban non-inferior to conventional treatment for VTE

July 1, 2013
ISTH: apixaban non-inferior to conventional treatment for VTE
For patients with venous thromboembolism, treatment with oral apixaban is non-inferior to conventional therapy for preventing recurrent venous thromboembolism or death related to venous thromboembolism, according to a study published online July 1 in the New England Journal of Medicine to coincide with presentation at the annual Congress of the International Society on Thrombosis and Haemostasis, held from June 29 to July 4 in Amsterdam.

(HealthDay)—For patients with venous thromboembolism, treatment with oral apixaban is non-inferior to conventional therapy for preventing recurrent venous thromboembolism or death related to venous thromboembolism, according to a study published online July 1 in the New England Journal of Medicine to coincide with presentation at the annual Congress of the International Society on Thrombosis and Haemostasis, held from June 29 to July 4 in Amsterdam.

Giancarlo Agnelli, M.D., from the University of Perugia in Italy, and colleagues conducted a randomized double-blind study to compare apixaban with subcutaneous , followed by warfarin (conventional therapy) in 5,395 patients with acute venous thromboembolism.

The researchers found that the primary efficacy outcome of recurrent symptomatic venous thromboembolism or death related to venous thromboembolism occurred in 2.3 and 2.7 percent of patients in the apixaban and conventional-therapy groups, respectively (relative risk, 0.84; 95 percent confidence interval, 0.60 to 1.18; difference in risk, ?0.4 percentage points; 95 percent confidence interval, ?1.3 to 0.4). For predefined upper limits of the 95 percent confidence intervals for both relative risk and difference in risk, apixaban was non-inferior to conventional therapy. Major bleeding occurred in significantly fewer patients in the apixaban group (0.6 versus 1.8 percent; relative risk, 0.31). The composite outcome of major bleeding and clinically relevant non-major bleeding occurred in significantly fewer patients in the apixaban group (4.3 versus 9.7 percent; relative risk, 0.44).

"A fixed-dose regimen of apixaban alone was non-inferior to for the treatment of acute venous thromboembolism and was associated with significantly less bleeding," the authors write.

The study was funded by Pfizer and Bristol-Myers Squibb, the manufacturers of .

Explore further: Prophylaxis with apixaban feasible for cancer patients

More information: Abstract
Full Text
Editorial
More Information

Related Stories

Prophylaxis with apixaban feasible for cancer patients

March 29, 2012
(HealthDay) -- Primary venous thromboembolism prophylaxis with apixaban, an oral direct Factor Xa inhibitor, in ambulatory cancer patients undergoing first- or second-line chemotherapy for advanced or metastatic cancer, is ...

New blood thinner may help prevent leg clots, study finds

December 10, 2012
(HealthDay)—The new anti-clotting drug apixaban (Eliquis) appears to help prevent potentially fatal blood clots in patients with deep vein thrombosis (DVT), a new Italian study finds.

Rivaroxaban found noninferior to enoxaparin in acutely ill

February 7, 2013
(HealthDay)—In acutely ill hospitalized patients, standard-duration rivaroxaban has similar efficacy as enoxaparin in reducing the risk of venous thromboembolism, while extended-duration rivaroxaban has superior efficacy, ...

Proof of added benefit of apixaban in hip replacement

September 17, 2012
The clot-inhibiting drug apixaban (trade name: Eliquis) was approved in May 2011 for the prevention of thrombosis (blood clots) after operations to replace a hip or knee joint. In an early benefit assessment pursuant to the ...

Apixaban superior to warfarin across range of patient risk scores

October 1, 2012
A new anticoagulant called apixaban is superior to warfarin in preventing stroke with consistent effects across a wide range of stroke and bleeding risk in patients with atrial fibrillation, according to Duke University Medical ...

Apixaban superior to warfarin for preventing stroke, reducing bleeding and saving lives

August 28, 2011
A large-scale trial finds that apixaban, a new anticoagulant drug, is superior to the standard drug warfarin for preventing stroke and systemic embolism in patients with atrial fibrillation. Moreover, apixaban results in ...

Recommended for you

Male hepatitis B patients suffer worse liver ailments, regardless of lifestyle

July 25, 2017
Why men with hepatitis B remain more than twice as likely to develop severe liver disease than women remains a mystery, even after a study led by a recent Drexel University graduate took lifestyle choices and environments ...

Mind-body therapies immediately reduce unmanageable pain in hospital patients

July 25, 2017
Mindfulness training and hypnotic suggestion significantly reduced acute pain experienced by hospital patients, according to a new study published in the Journal of General Internal Medicine.

Researchers report new system to study chronic hepatitis B

July 25, 2017
Scientists from Princeton University's Department of Molecular Biology have successfully tested a cell-culture system that will allow researchers to perform laboratory-based studies of long-term hepatitis B virus (HBV) infections. ...

Research examines lung cell turnover as risk factor and target for treatment of influenza pneumonia

July 24, 2017
Influenza is a recurring global health threat that, according to the World Health Organization, is responsible for as many as 500,000 deaths every year, most due to influenza pneumonia, or viral pneumonia. Infection with ...

Scientists propose novel therapy to lessen risk of obesity-linked disease

July 24, 2017
With obesity related illnesses a global pandemic, researchers propose in the Journal of Clinical Investigation using a blood thinner to target molecular drivers of chronic metabolic inflammation in people eating high-fat ...

Raccoon roundworm—a hidden human parasite?

July 24, 2017
The raccoon that topples your trashcan and pillages your garden may leave more than just a mess. More likely than not, it also contaminates your yard with parasites—most notably, raccoon roundworms (Baylisascaris procyonis).

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.